Pages that link to "Q37042563"

The following pages link to Development of prophylactic vaccines against HIV-1. (Q37042563):

Displayed 49 items.

• Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective (Q26770839) ‎ (← links)
• Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) ‎ (← links)
• Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (Q27319450) ‎ (← links)
• Status of vaccine research and development of vaccines for HIV-1. (Q30385813) ‎ (← links)
• Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy (Q33611645) ‎ (← links)
• Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques (Q33683203) ‎ (← links)
• Which Antibody Functions are Important for an HIV Vaccine? (Q33772637) ‎ (← links)
• Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination (Q34022578) ‎ (← links)
• Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3. (Q34046807) ‎ (← links)
• Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production (Q34055377) ‎ (← links)
• Sex-based differences in HIV type 1 pathogenesis (Q34148475) ‎ (← links)
• Mucosal immunity in the female genital tract, HIV/AIDS (Q34275424) ‎ (← links)
• In pursuit of an HIV vaccine: an interview with Andrew McMichael (Q34345870) ‎ (← links)
• Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity (Q34555891) ‎ (← links)
• Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells (Q34594624) ‎ (← links)
• Thirty years on: HIV receptor gymnastics and the prevention of infection (Q34732816) ‎ (← links)
• Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities (Q35013490) ‎ (← links)
• Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. (Q35058860) ‎ (← links)
• Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays (Q35070898) ‎ (← links)
• Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent (Q35686912) ‎ (← links)
• The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection (Q35686970) ‎ (← links)
• Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens (Q36434196) ‎ (← links)
• Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens (Q36736400) ‎ (← links)
• The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms (Q37057983) ‎ (← links)
• The Art of HIV Elimination: Past and Present Science (Q37354106) ‎ (← links)
• Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA. (Q37714080) ‎ (← links)
• Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. (Q37729781) ‎ (← links)
• Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies (Q38154038) ‎ (← links)
• Human immunodeficiency virus antibodies and the vaccine problem. (Q38192126) ‎ (← links)
• Modeling T cell responses to antigenic challenge (Q38255612) ‎ (← links)
• Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs (Q38260862) ‎ (← links)
• An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine (Q38283531) ‎ (← links)
• Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. (Q38296086) ‎ (← links)
• A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus (Q38353693) ‎ (← links)
• Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice (Q39407795) ‎ (← links)
• Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. (Q40130744) ‎ (← links)
• Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. (Q40442031) ‎ (← links)
• Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial (Q40545310) ‎ (← links)
• HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution (Q40940285) ‎ (← links)
• HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein (Q41138686) ‎ (← links)
• A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice (Q41424896) ‎ (← links)
• Functional conservation of HIV-1 Gag: implications for rational drug design (Q41822002) ‎ (← links)
• Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1. (Q45325097) ‎ (← links)
• Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins (Q47144668) ‎ (← links)
• A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system (Q47549087) ‎ (← links)
• Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. (Q55401174) ‎ (← links)
• Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India (Q57167018) ‎ (← links)
• Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes (Q92184345) ‎ (← links)
• Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization (Q92538999) ‎ (← links)